



Nevada Medicaid – Molina Healthcare

Immunomodulator Drugs Prior Authorization Request Form

Please provide the information below, please print your answer, attach supporting documentation, sign, date, and return to our office as soon as possible to expedite this request. **Please FAX responses to: (844) 259-1689. Phone: (833) 685-2103.**

Member Information <small>(required)</small>			Provider Information <small>(required)</small>		
Member Name:			Provider Name:		
Molina ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information <small>(required)</small>			
Medication Name:		Strength:	Dosage Form:
<input type="checkbox"/> Check if request is for continuation of therapy		Directions for Use:	

Clinical Information <small>(required)</small>
<p>Clinical information required for all indications:</p> <ul style="list-style-type: none"> <input type="checkbox"/> The recipient has had a negative tuberculin test <input type="checkbox"/> The recipient does not have an active infection or a history of recurring infections <input type="checkbox"/> Only one biologic medication is being used <p>Rheumatoid Arthritis:</p> <ul style="list-style-type: none"> <input type="checkbox"/> The recipient has a diagnosis of moderately to severely active RA <input type="checkbox"/> The recipient is 18 years of age or older <input type="checkbox"/> The recipient has had a rheumatology consultation, including the date of the visit: _____ <p>Choose one of the following:</p> <ul style="list-style-type: none"> <input type="checkbox"/> The recipient has had RA for < six months (early RA) and has high disease activity; and an inadequate or adverse reaction to a disease modifying antirheumatic drug (DMARD) (methotrexate, hydroxychloroquine, leflunomide, minocycline and sulfasalazine) <input type="checkbox"/> The recipient has had RA for > six months (intermediate or long-term disease duration) and has moderate disease activity and has an inadequate response to a DMARD (methotrexate, hydroxychloroquine, leflunomide, minocycline or sulfasalazine) <input type="checkbox"/> The recipient has had RA for > six months (intermediate or long-term disease duration) and has high disease activity <p>Psoriatic Arthritis:</p> <ul style="list-style-type: none"> <input type="checkbox"/> The recipient has a diagnosis of moderate or severe psoriatic arthritis <input type="checkbox"/> The recipient is 18 years of age or older <input type="checkbox"/> The recipient has had a rheumatology consultation including the date of the visit or a dermatology consultation including the date of the visit: _____ <input type="checkbox"/> The recipient had an inadequate response or a contraindication to treatment with any one nonsteroidal anti-inflammatory (NSAID) or to any one of the following DMARDs: methotrexate, leflunomide, cyclosporine or sulfasalazine <p>Ankylosing Spondylitis:</p> <ul style="list-style-type: none"> <input type="checkbox"/> The recipient has a diagnosis of ankylosing spondylitis <input type="checkbox"/> The recipient is 18 years of age or older <input type="checkbox"/> The recipient has had an inadequate response to NSAIDs <input type="checkbox"/> The recipient has had an inadequate response to any one of the DMARDs (methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, minocycline)

Clinical Information Cont. (required)

Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis:

- The recipient has a diagnosis of moderately or severely active juvenile RA or juvenile idiopathic arthritis
- The recipient is at an appropriate age, based on the requested agent:
 - Abatacept: Six years of age or older
 - Adalimumab, canakinumab, etanercept, tocilizumab: Two years of age or older
- The recipient has at least five swollen joints
- The recipient has three or more joints with limitation of motion and pain, tenderness or both
- The recipient has had an inadequate response to one DMARD

Plaque Psoriasis:

- The recipient has a diagnosis of chronic, moderate to severe plaque psoriasis;
- The recipient is 18 years of age or older
- The agent is prescribed by a dermatologist
- The recipient has failed to adequately respond to a topical agent
- The recipient has failed to adequately respond to at least one oral treatment

Crohn's Disease:

- The recipient has a diagnosis of moderate to severe Crohn's Disease
- The recipient is at an appropriate age, based on the requested agent:
 - Abatacept, infliximab: Six years of age or older
 - All others: 18 years of age or older.
- The recipient has failed to adequately respond to conventional therapy (e.g. sulfasalazine, mesalamine, antibiotics, corticosteroids, azathioprine, 6-mercaptopurine, leflunomide)
- The recipient has fistulizing Crohn's Disease

Ulcerative Colitis:

- The recipient has a diagnosis of moderate to severe ulcerative colitis
- The recipient is at an appropriate age, based on the requested agent:
 - Infliximab: Six years of age or older
 - All others: 18 years of age or older.
- The recipient has failed to adequately respond to one or more of the following standard therapies: Corticosteroid, 5-aminosalicylic acid agents, immunosuppressants and/or Thiopurines.

Cryopyrin-Associated Periodic Syndromes (CAPS): Familial Cold Autoinflammatory Syndromes (FCAS) or Muckle-Wells Syndrome (MWS)

- The recipient has a diagnosis of FCAS or MWS
- The recipient is at an appropriate age, based on the requested agent:
 - Canakinumab: Four years of age or older
 - Riloncept: 12 years of age or older.

Cryopyrin-Associated Periodic Syndromes (CAPS): Neonatal-Onset Multisystem Inflammatory Disease (NOMID):

- The recipient has a diagnosis of NOMID

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note:

This request may be denied unless all required information is received.
For urgent or expedited requests please call (833) 685-2103.
This form may be used for non-urgent requests and faxed to (844) 259-1689.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of Molina Healthcare. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**